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Purpose of the study
Three nucleoside reverse transcriptase inhibitor (NRTI)
pairs are commonly used in the UK in people with HIV
infection naïve to antiretroviral treatment. This analysis
evaluated lifetime health outcomes, costs, and cost-effec-
tiveness associated with once-daily tenofovir DF/emtricit-
abine (TDF/FTC), twice-daily zidovudine/lamivudine
(ZDV/3TC), and once-daily abacavir/lamivudine (ABC/
3TC).
Methods
Results of head-to-head clinical trials of TDF/FTC vs. ZDV/
3TC (144-week results of Study 934) and ABC/3TC vs.
ZDV/3TC (normalized 48-week results of Study
CNA30024) were used to populate a Markov model that
estimated lifetime costs and health outcomes for treat-
ment-naïve individuals. Virologic response (< 400 copies/
mL) over time was estimated by fitting exponential curves
to trial data; individuals with viral load levels above 400
copies/mL switched to second-line treatment. Immune
response data were used to calculate transition probabili-
ties between six health states based on CD4 cell-count
ranges. Subsequent therapy lines were modeled using
likely baskets of second-line, third-line, and non-suppres-
sive therapy regimens. Utility values, mortality rates, drug
costs and other direct medical costs were obtained from
published sources. Adverse events observed in Studies 934
and CNA30024 were accounted for in modeled costs and
outcomes. Base-case results were tested in one-way and
probabilistic sensitivity analyses.
Summary of results
Individuals using TDF/FTC were predicted to remain on
first-line therapy for an average of 5.9 years compared
with 4.9 years and 4.8 years, respectively, for those using
ABC/3TC and ZDV/3TC. Individuals using TDF/FTC were
predicted to accrue total lifetime costs of £267,603 and
experience 14.50 quality-adjusted life-years (QALYs), on
average, compared with £269,487 and 14.38 QALYs and
£266,785 and 14.20 QALYs for ABC/3TC and ZDV/3TC,
respectively. The resulting cost-utility ratios were -£15,525
and £2,727 per QALY gained for TDF/FTC compared with
ABC/3TC and ZDV/3TC, respectively.
Conclusion
TDF/FTC was predicted to be both more effective and cost
saving compared with ABC/3TC and to be cost-effective,
using a threshold of £20,000 per QALY gained, compared
with ZDV/3TC in treatment-naïve adults with HIV infec-
tion in the UK. In addition, TDF/FTC offers convenient,
once-daily dosing. Results were driven by better efficacy
and tolerability of TDF/FTC compared with the other
NRTI pairs.
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